Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.

Yufan ZhouChong YanXinyu GuLei ZhouJun LuWenhua ZhuXiao HuanSushan LuoHuahua ZhongJie LinJiahong LuChong-Bo ZhaoJianying Xi

Published in: Muscle & nerve (2021)

We confirmed the clinical efficacy of low-dose rituximab in MuSK-MG, accompanied by a decrease in MuSK antibody titers and an increase in serum BAFF. Serum BAFF levels negatively correlated with B-cell counts as well as clinical severity.

Keyphrases

low dose
tyrosine kinase
myasthenia gravis
diffuse large b cell lymphoma
epidermal growth factor receptor
high dose
hodgkin lymphoma
chronic lymphocytic leukemia
skeletal muscle
peripheral blood